Posts tagged ‘Biotech Market Analysis’

Last week, Biotech Strategy Blog celebrated one year of publication!

Two of the most read posts on Biotech Strategy Blog in its first year were:

• Lucentis v Avastin CATT trial results in AMD (briefing at ARVO)
• Prostate Cancer Intervention versus Observation (PIVOT) trial data (presented in plenary session at AUA)

You can read more on Biotech Strategy Blog about the top posts of the past year. Some of the topics Pieter Droppert has most enjoyed writing about include: radium-223 (Alpharadin) and use of nanotechnology to detect blast injuries.

We look forward to further coverage of news from medical and scientific congresses on Biotech Strategy Blog as it enters a second year.

Pieter will be at the AACR-NCI-EORTC molecular targets and cancer therapeutics meeting in San Francisco in two weeks time.